资料单张
NATROPHYLLINE® COMPOUND TABLETS
SCHEDULING STATUS:
S1
PROPRIETARY NAME
(and dosage form):
NATROPHYLLINE
®
COMPOUND TABLETS
COMPOSITION:
Each tablet contains:
Theophylline with Ethylenediamine
100 mg
Ephedrine Hydrochloride
225 mg
Phenobarbitone (PHENOBARBITAL)
15 mg
PHARMACOLOGICAL CLASSIFICATION:
A 10.2.2 Medicines acting on respiratory system - Other.
PHARMACOLOGICAL ACTION:
Theophylline with ethylenediamine and ephedrine hydrochloride act additively to stimulate respiration and relax the
bronchial muscles in bronchial spasm. Phenobarbitone is added to counteract the combined central stimulant actions of
the above mentioned drugs.
INDICATIONS:
For the symptomatic relief of bronchial spasm associated with asthma, bronchial asthma, bronchopneumonia and
bronchitis. It may be given over prolonged periods to reduce the number and severity of attacks.
CONTRA-INDICATIONS:
Patients with coronary thrombosis, hypertension, porphyria and thyrotoxicosis, and those receiving monoamine oxidase
inhibitors.
DOSAGE AND DIRECTIONS FOR USE:
One to two tablets or as prescribed.
Not for children under 12 years of age.
SIDE-EFFECTS AND SPECIAL PRECAUTIONS:
Side-effects may include gastric irritation with nausea and vomiting. Some patients exhibit an idiosyncrasy to
phenobarbitone and in such individuals, phenobarbitone may cause restlessness and excitement
Natrophylline Compound tablets should be administered with caution to patients suffering from cardiac disease and
impaired liver or renal function.
KNOWN SYMPTOMS OF OVERDOSAGE AND PARTICULARS OF ITS TREATMENT:
Overdosage with Natrophylline Compound tablets may cause nausea, vomiting, gastro-intestinal bleeding and
palpitations.
In cases of severe toxicity, the stomach should be emptied by gastric lavage. Respiration and electrolyte balance should
be maintained.
IDENTIFICATIO
阅读完整的文件
资料单张 